BRAF and colonic neoplasm: Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAF<sup>V600E</sup> mutated, microsatellite-stable colon cancer.